» Articles » PMID: 24686252

Investigation of the in Vitro Toxicological Properties of the Synthetic Cannabimimetic Drug CP-47,497-C8

Overview
Specialties Pharmacology
Toxicology
Date 2014 Apr 2
PMID 24686252
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Cannabicyclohexanol (CP-47,497-C8) is a representative of a group of cannabimimetic cyclohexylphenols which is added to herbal mixtures as a cannabis substitute since 2008. Although in the beginning CP-47,497-C8 was the main ingredient of "Spice" and similar products, it was partly replaced by aminoalkylindole-type cannabinoid receptor agonists like JWH-018, JWH-073 or JWH-250, but never completely disappeared from the market. Since information on its toxicological properties is scarce, we investigated the effects of the drug in human derived cell lines. The cytotoxic effects were studied in a panel of assays (SRB, XTT, LDHe and NR tests) in a buccal derived (TR146) and a liver derived (HepG2) cell line. The strongest effects were seen in the two former assays at levels ≥ 7.5 μM indicating that the compound interferes with protein synthesis and causes membrane damage. In additional comet assays, DNA damage was detected at levels ≥10 μM. Experiments with lesion specific enzymes showed that these effects are not due to oxidative damage of DNA bases. The negative findings obtained in Salmonella/microsome assays and the positive results of micronucleus tests with the cell lines indicate that the compound does not cause gene mutations but acts on the chromosomal level. In contrast to other synthetic cannabinoids, no indication for estrogenic/antiestrogenic properties was seen in a luciferase assay with bone marrow derived U2-OS cells. In conclusion, our findings show that the drug has only weak cytotoxic properties. However, the induction of chromosomal damage indicates that it may cause adverse effects in users due to its impact on the stability of the genetic material.

Citing Articles

Perturbation of 3D nuclear architecture, epigenomic dysregulation and aging, and cannabinoid synaptopathy reconfigures conceptualization of cannabinoid pathophysiology: part 1-aging and epigenomics.

Reece A, Hulse G Front Psychiatry. 2023; 14:1182535.

PMID: 37732074 PMC: 10507876. DOI: 10.3389/fpsyt.2023.1182535.


Clinical Epigenomic Explanation of the Epidemiology of Cannabinoid Genotoxicity Manifesting as Transgenerational Teratogenesis, Cancerogenesis and Aging Acceleration.

Reece A, Hulse G Int J Environ Res Public Health. 2023; 20(4).

PMID: 36834053 PMC: 9967951. DOI: 10.3390/ijerph20043360.


Geospatiotemporal and Causal Inferential Study of European Epidemiological Patterns of Cannabis- and Substance-Related Congenital Orofacial Anomalies.

Reece A, Hulse G J Xenobiot. 2023; 13(1):42-74.

PMID: 36810431 PMC: 9944119. DOI: 10.3390/jox13010006.


Patterns of Cannabis- and Substance-Related Congenital General Anomalies in Europe: A Geospatiotemporal and Causal Inferential Study.

Reece A, Hulse G Pediatr Rep. 2023; 15(1):69-118.

PMID: 36810339 PMC: 9944887. DOI: 10.3390/pediatric15010009.


Human Astrocyte Spheroids as Suitable In Vitro Screening Model to Evaluate Synthetic Cannabinoid MAM2201-Induced Effects on CNS.

De Simone U, Pignatti P, Villani L, Russo L, Sargenti A, Bonetti S Int J Mol Sci. 2023; 24(2).

PMID: 36674936 PMC: 9861655. DOI: 10.3390/ijms24021421.